• bitcoinBitcoin(BTC)$80,373.003.00%
  • ethereumEthereum(ETH)$2,414.004.79%
  • tetherTether(USDT)$1.000.06%
  • binancecoinBNB(BNB)$712.121.45%
  • rippleXRP(XRP)$1.312.96%
  • usd-coinUSDC(USDC)$1.000.04%
  • solanaSolana(SOL)$95.853.08%
  • tronTRON(TRX)$0.318401-1.02%
  • Figure HelocFigure Heloc(FIGR_HELOC)$1.051.52%
  • zcashZcash(ZEC)$1,320.643.01%
  • HyperliquidHyperliquid(HYPE)$83.29-2.22%
  • dogecoinDogecoin(DOGE)$0.0764001.99%
  • moneroMonero(XMR)$635.30-0.48%
  • USDSUSDS(USDS)$1.000.04%
  • whitebitWhiteBIT Coin(WBT)$77.723.51%
  • chainlinkChainlink(LINK)$11.533.55%
  • leo-tokenLEO Token(LEO)$9.360.58%
  • cardanoCardano(ADA)$0.1971893.26%
  • stellarStellar(XLM)$0.1660601.70%
  • bitcoin-cashBitcoin Cash(BCH)$284.783.35%
  • nearNEAR Protocol(NEAR)$4.020.19%
  • uniswapUniswap(UNI)$7.591.36%
  • daiDai(DAI)$1.000.02%
  • Ethena USDeEthena USDe(USDE)$1.000.06%
  • litecoinLitecoin(LTC)$55.882.35%
  • RainRain(RAIN)$0.005803-6.96%
  • CantonCanton(CC)$0.1026233.29%
  • avalanche-2Avalanche(AVAX)$8.741.96%
  • suiSui(SUI)$0.922.13%
  • USD1USD1(USD1)$1.000.01%
  • the-open-networkGram (prev. Toncoin)(GRAM)$1.17-0.76%
  • tether-goldTether Gold(XAUT)$4,103.182.30%
  • hedera-hashgraphHedera(HBAR)$0.0726493.39%
  • quant-networkQuant(QNT)$205.185.72%
  • Global DollarGlobal Dollar(USDG)$1.000.03%
  • shiba-inuShiba Inu(SHIB)$0.0000050.76%
  • BittensorBittensor(TAO)$234.852.59%
  • paypal-usdPayPal USD(PYUSD)$1.000.04%
  • crypto-com-chainCronos(CRO)$0.0522723.40%
  • Ripple USDRipple USD(RLUSD)$1.000.04%
  • EthenaEthena(ENA)$0.180127-0.83%
  • Ondo US Dollar YieldOndo US Dollar Yield(USDY)$1.15-0.16%
  • okbOKB(OKB)$110.882.26%
  • Circle USYCCircle USYC(USYC)$1.140.01%
  • pepePepe(PEPE)$0.000005-1.38%
  • aaveAave(AAVE)$132.471.38%
  • OndoOndo(ONDO)$0.4064311.41%
  • Pump.funPump.fun(PUMP)$0.004291-2.45%
  • MemeCoreMemeCore(M)$0.83-2.25%
  • BlackRock USD Institutional Digital Liquidity FundBlackRock USD Institutional Digital Liquidity Fund(BUIDL)$1.000.00%
TradePoint.io
  • Main
  • AI & Technology
  • Stock Charts
  • Market & News
  • Business
  • Finance Tips
  • Trade Tube
  • Blog
  • Shop
No Result
View All Result
TradePoint.io
No Result
View All Result

Advances and Challenges in Predicting TCR Specificity: From Clustering to Protein Language Models

July 29, 2024
in AI & Technology
Reading Time: 4 mins read
A A
Advances and Challenges in Predicting TCR Specificity: From Clustering to Protein Language Models
ShareShareShareShareShare

Recent advances in immune sequencing and experimental methods generate extensive T cell receptor (TCR) repertoire data, enabling models to predict TCR binding specificity. T cells play a role in the adaptive immune system, orchestrating targeted immune responses through TCRs that recognize non-self antigens from pathogens or diseased cells. TCR diversity, essential for recognizing diverse antigens, is generated through random DNA rearrangement involving V, D, and J gene segments. While theoretical TCR diversity is extremely high, the actual diversity in an individual is much smaller. TCRs interact with peptides on the major histocompatibility complex (pMHC), with some TCRs recognizing numerous pMHC complexes.

Researchers from IBM Research Europe, the Institute of Computational Life Sciences at Zürich University of Applied Sciences, and Yale School of Medicine review the evolution of computational models for predicting TCR binding specificity. Emphasizing machine learning, they cover early unsupervised clustering approaches, supervised models, and the transformative impact of Protein Language Models (PLMs) in bioinformatics, particularly in TCR specificity analysis. The review addresses dataset biases, generalization issues, and model validation shortcomings. It highlights the importance of improving model interpretability and extracting biological insights from large, complex models to enhance TCR-pMHC binding predictions and revolutionize immunotherapy development.

YOU MAY ALSO LIKE

OpenAI’s Enterprise Sales Take Majority as Brockman Sees IPO Readiness – Unite.AI

Cat Wu to Lead Product Management for OpenAI’s Core Products – Unite.AI

TCR specificity data comes from databases like VDJdb and McPas-TCR, but these datasets have significant limitations. Bulk sequencing is high-throughput and cost-effective but can’t detect paired α and β chains, while single-cell technologies that can are expensive and underrepresented. Most datasets focus on a limited number of epitopes, predominantly of viral origin and associated with common HLA alleles, showing significant bias. Additionally, the lack of negative data complicates supervised machine learning model development. Generating artificial negative pairs introduces biases, and high-performance models can memorize sequences, leading to over-optimistic results. Ensuring generated negative pairs accurately reflect true non-binding distributions remains a challenge.

Since 2017, the modeling of TCR specificity has evolved significantly, beginning with unsupervised clustering methods. Initial models like TCRdist and GLIPH grouped TCRs based on sequence similarities and biochemical properties. These methods demonstrated that TCR sequences contain valuable specificity information, but they struggled with complex nonlinear interactions. This prompted the development of supervised models that utilized machine learning techniques to handle the increasing complexity of data better. Early supervised models, including TCRGP and TCRex, employed classifiers such as Gaussian Processes and random forests to predict TCR specificity. Meanwhile, neural network-based approaches like NetTCR and DeepTCR leveraged advanced architectures to enhance predictive accuracy.

The introduction of PLMs marked the latest advancement in TCR specificity prediction. Based on Transformer architectures, these models were trained on extensive protein sequence datasets, achieving remarkable performance in various protein-related tasks. TCR-BERT and STAPLER, for example, utilized BERT-based models fine-tuned for TCR and antigen classification, demonstrating the effectiveness of PLMs in capturing complex sequence interactions. Despite their success, challenges remain in addressing lexical ambiguity and enhancing model interpretability. Future improvements in embedding optimization and adaptation of interpretability methods specific to protein sequences are crucial for further advancements in TCR specificity prediction.

Accurate TCR specificity prediction is vital for improving immunotherapies and understanding autoimmune diseases. Limited and biased data, particularly epitope information, challenge current models, hindering generalization to new epitopes. Advances in machine learning, including CNNs, RNNs, transfer learning, and PLMs, have significantly enhanced TCR prediction models, but challenges remain, especially in predicting specificity for novel epitopes. Benchmarks like IMMREP22 and IMMREP23 highlight difficulties in fair model comparison and generalizability. Adapting TCR models for BCR prediction, which involves non-linear epitopes and complex antigen interactions, presents further computational challenges.


Check out the Paper. All credit for this research goes to the researchers of this project. Also, don’t forget to follow us on Twitter and join our Telegram Channel and LinkedIn Group. If you like our work, you will love our newsletter..

Don’t Forget to join our 47k+ ML SubReddit

Find Upcoming AI Webinars here


Sana Hassan, a consulting intern at Marktechpost and dual-degree student at IIT Madras, is passionate about applying technology and AI to address real-world challenges. With a keen interest in solving practical problems, he brings a fresh perspective to the intersection of AI and real-life solutions.

🐝 Join the Fastest Growing AI Research Newsletter Read by Researchers from Google + NVIDIA + Meta + Stanford + MIT + Microsoft and many others…


Credit: Source link

ShareTweetSendSharePin

Related Posts

OpenAI’s Enterprise Sales Take Majority as Brockman Sees IPO Readiness – Unite.AI
AI & Technology

OpenAI’s Enterprise Sales Take Majority as Brockman Sees IPO Readiness – Unite.AI

November 5, 2026
Cat Wu to Lead Product Management for OpenAI’s Core Products – Unite.AI
AI & Technology

Cat Wu to Lead Product Management for OpenAI’s Core Products – Unite.AI

November 5, 2026
Amodei Wins Dismissal of Direct Copyright Claim with Leave to Amend – Unite.AI
AI & Technology

Amodei Wins Dismissal of Direct Copyright Claim with Leave to Amend – Unite.AI

November 5, 2026
Snap Has More Than 30 Million Paid Subscribers Across Snapchat+ And Other Plans
AI & Technology

Snap Has More Than 30 Million Paid Subscribers Across Snapchat+ And Other Plans

November 4, 2026
Next Post
Second Gentleman Doug Emhoff highlights how men can help in the fight for abortion rights

Second Gentleman Doug Emhoff highlights how men can help in the fight for abortion rights

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Search

No Result
View All Result
2026 Elections Live Updates: Candidates Campaign in Battleground States on Final Weekend – The New York Times

2026 Elections Live Updates: Candidates Campaign in Battleground States on Final Weekend – The New York Times

October 31, 2026
The Superforecasters: With Guests Leon Panetta, Peter Bergen & Barbara Mellers (Rebroadcast)

The Superforecasters: With Guests Leon Panetta, Peter Bergen & Barbara Mellers (Rebroadcast)

November 2, 2026
Video shows moment of deadly Florida bus crash

Video shows moment of deadly Florida bus crash

October 31, 2026

About

Learn more

Our Services

Legal

Privacy Policy

Terms of Use

Bloggers

Learn more

Article Links

Contact

Advertise

Ask us anything

©2020- TradePoint.io - All rights reserved!

Tradepoint.io, being just a publishing and technology platform, is not a registered broker-dealer or investment adviser. So we do not provide investment advice. Rather, brokerage services are provided to clients of Tradepoint.io by independent SEC-registered broker-dealers and members of FINRA/SIPC. Every form of investing carries some risk and past performance is not a guarantee of future results. “Tradepoint.io“, “Instant Investing” and “My Trading Tools” are registered trademarks of Apperbuild, LLC.

This website is operated by Apperbuild, LLC. We have no link to any brokerage firm and we do not provide investment advice. Every information and resource we provide is solely for the education of our readers. © 2020 Apperbuild, LLC. All rights reserved.

No Result
View All Result
  • Main
  • AI & Technology
  • Stock Charts
  • Market & News
  • Business
  • Finance Tips
  • Trade Tube
  • Blog
  • Shop

© 2023 - TradePoint.io - All Rights Reserved!